Cue Biopharma (CUE) Stock Price, News & Analysis

Company Overview

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies. Its most advanced candidate, CUE-101, is an HLA‐peptide‐cytokine fusion designed to stimulate T cells specific to HPV16‐positive cancers. Additional programs—such as CUE-102 and CUE-301—seek to address solid tumors and viral infections by harnessing the same platform technology to selectively expand disease-relevant T cell populations. The company’s research and manufacturing activities are conducted primarily in the United States, with collaborations and partnerships aimed at accelerating clinical development.

Under the leadership of President and CEO Darren Cline, Cue Biopharma has completed its initial public offering in 2021 and continues to build its research capabilities through strategic alliances with academic institutions and contract development organizations. The management team combines expertise in immunology, protein engineering and clinical development, positioning the company to advance its pipeline toward key clinical milestones. With its unique CRT platform, Cue Biopharma seeks to offer differentiated, antigen‐specific immunotherapies that may overcome limitations of current cytokine and cell‐based treatments.

Key Stats

• Today's Range: $0.77 to $0.79
• 50-Day Range: $0.67 to $0.91
• 52-Week Range: $0.45 to $1.99
• Volume: 64,031 shs
• Average Volume: 249,011 shs
• Market Capitalization: $59.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cue Biopharma Stock Analysis - MarketRank™

Cue Biopharma scored higher than 32% of companies evaluated by MarketBeat, and ranked 792nd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cue Biopharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cue Biopharma is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cue Biopharma is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cue Biopharma has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.25% of the outstanding shares of Cue Biopharma have been sold short.

Short Interest Ratio / Days to Cover

Cue Biopharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cue Biopharma has recently increased by 10.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cue Biopharma does not currently pay a dividend.

Dividend Growth

Cue Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.58

Percentage of Shares Shorted

1.25% of the outstanding shares of Cue Biopharma have been sold short.

Short Interest Ratio / Days to Cover

Cue Biopharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cue Biopharma has recently increased by 10.86%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Cue Biopharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cue Biopharma this week, compared to 1 article on an average week.

Search Interest

5 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cue Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.04% of the stock of Cue Biopharma is held by institutions.

CUE Stock Analysis - Frequently Asked Questions

How have CUE shares performed this year?

Cue Biopharma's stock was trading at $1.09 at the beginning of 2025. Since then, CUE stock has decreased by 28.3% and is now trading at $0.7820.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. The firm earned $2.95 million during the quarter, compared to the consensus estimate of $2 million. Cue Biopharma had a negative net margin of 469.35% and a negative trailing twelve-month return on equity of 230.13%.

Who are Cue Biopharma's major shareholders?

Top institutional investors of Cue Biopharma include GC Wealth Management RIA LLC (4.42%), Angeles Wealth Management LLC (0.16%), Northwestern Mutual Wealth Management Co. (0.11%) and Group One Trading LLC. Insiders that own company stock include Daniel R Passeri, Anish Suri and Peter A Kiener.
View institutional ownership trends.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/08/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CUE
• CIK: 1645460
• Web: www.cuebiopharma.com
• Phone: (617) 949-2680
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.67 million
• Net Margins: -469.35%
• Pretax Margin: -469.35%
• Return on Equity: -230.13%
• Return on Assets: -111.16%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.60
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $9.29 million
• Price / Sales: 6.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 2.77

Miscellaneous

• Outstanding Shares: 76,850,000
• Free Float: 67,425,000
• Market Cap: $59.56 million
• Optionable: Optionable
• Beta: 1.58